Related Experiment Video
Updated: Jul 2, 2026
07:10
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
Association between angiotensin-converting enzyme gene polymorphisms and exercise performance in patients with COPD
Xiaolei Zhang1, Chen Wang, Huaping Dai
1Beijing Institute of Respiratory Medicine, Beijing Chaoyang Hospital, Beijing, China.
Respirology (Carlton, Vic.)
|August 21, 2008
Summary
The angiotensin-converting enzyme (ACE) gene influences skeletal muscle aerobic work efficiency in COPD patients, but not their exercise ventilatory response. This finding highlights the ACE gene's role in COPD exercise capacity.
Area of Science:
- Pulmonary Medicine
- Genetics
- Exercise Physiology
Background:
- Polymorphisms in the angiotensin-converting enzyme (ACE) gene are linked to pulmonary disorders.
- The ACE gene regulates inflammatory responses, respiratory drive, and oxygenation, impacting lung injury recovery.
- The study hypothesized an association between ACE gene variants and exercise response in COPD patients.
Purpose of the Study:
- To investigate the association between ACE gene polymorphisms and ventilatory response to exercise.
- To examine the relationship between ACE gene variants and skeletal muscle aerobic work efficiency in COPD patients.
Main Methods:
- Sixty-one COPD patients and 57 healthy controls underwent incremental cardiopulmonary exercise testing.
- ACE genotypes were identified using polymerase chain reaction (PCR) amplification.
- Analysis compared exercise parameters across different ACE genotypes in both COPD and control groups.
Main Results:
- No significant differences in resting lung function or blood gases were observed among ACE genotype groups in COPD patients.
- Ventilatory responses to exercise and maximal oxygen uptake did not differ significantly across ACE genotypes in COPD patients.
- Maximal workload and aerobic work efficiency were higher in COPD patients with the ACE II genotype compared to ID or DD genotypes.
Conclusions:
- The ACE gene appears to play a role in regulating skeletal muscle aerobic work efficiency in COPD.
- The ACE gene is not associated with ventilatory responses to exercise in patients with COPD.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:20Exercise and Cardiovascular Response
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...